Shuttle Pharmaceuticals Subsidiary Expands Data Centers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Infrastructure Expansion Plans: Shuttle Pharmaceuticals' subsidiary United Dogecoin plans to expand data centers and power assets in Idaho and Alberta, aiming to support cryptocurrency mining and create capacity for commercial AI computing, signaling a strategic shift that led to a 44% stock price increase in after-hours trading.
- Triller Group's Space Investment: Triller Group announced the acquisition of an investment vehicle providing indirect exposure to SpaceX, resulting in a 296% surge during regular trading and an additional 30% in after-hours, reflecting strong investor enthusiasm for the company's high-value balance sheet strategy, with retail sentiment shifting from neutral to extremely bullish.
- INVO Fertility's Full Ownership: INVO Fertility completed the acquisition of its remaining joint-venture interest in an Alabama fertility clinic and resolved a Nasdaq compliance issue, leading to a 50% increase in after-hours trading, indicating heightened investor confidence in the reproductive healthcare sector, with retail sentiment improving from neutral to bullish.
- Strong Performance of Small Caps: Despite SHPH and IVF stocks declining 79% and 67% year-to-date, respectively, ILLR stock has surged 853%, demonstrating robust market interest in small-cap stocks and positive investor reactions to specific company developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SHPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SHPH
About SHPH
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Infrastructure Expansion Plans: Shuttle Pharmaceuticals' subsidiary United Dogecoin plans to expand data centers and power assets in Idaho and Alberta, aiming to support cryptocurrency mining and create capacity for commercial AI computing, signaling a strategic shift that led to a 44% stock price increase in after-hours trading.
- Triller Group's Space Investment: Triller Group announced the acquisition of an investment vehicle providing indirect exposure to SpaceX, resulting in a 296% surge during regular trading and an additional 30% in after-hours, reflecting strong investor enthusiasm for the company's high-value balance sheet strategy, with retail sentiment shifting from neutral to extremely bullish.
- INVO Fertility's Full Ownership: INVO Fertility completed the acquisition of its remaining joint-venture interest in an Alabama fertility clinic and resolved a Nasdaq compliance issue, leading to a 50% increase in after-hours trading, indicating heightened investor confidence in the reproductive healthcare sector, with retail sentiment improving from neutral to bullish.
- Strong Performance of Small Caps: Despite SHPH and IVF stocks declining 79% and 67% year-to-date, respectively, ILLR stock has surged 853%, demonstrating robust market interest in small-cap stocks and positive investor reactions to specific company developments.
See More

- Successful Merger: E.F. Hutton served as the exclusive advisor for Shuttle Pharmaceuticals' acquisition of United Dogecoin, creating one of the largest publicly traded Dogecoin mining platforms, thereby enhancing market competitiveness.
- Financing Support: In this transaction, E.F. Hutton also acted as the placement agent for a $9.6 million PIPE financing, providing critical growth capital to support the acquisition of mining equipment and the expansion of energy-efficient infrastructure.
- Technological Upgrade: The newly deployed ElphaPex mining rigs are expected to be fully operational within 60 days, delivering up to 43,200 GH/s of hash rate, significantly enhancing the company's mining capabilities and market position.
- Strategic Integration: E.F. Hutton provided comprehensive advisory services on transaction structure, terms, and capital raising, ensuring strategic alignment between both management teams and delivering integrated solutions for complex cross-sector transactions.
See More
- Successful Merger: E.F. Hutton served as the exclusive advisor for Shuttle Pharmaceuticals' acquisition of United Dogecoin, creating one of the largest publicly traded Dogecoin mining platforms, marking a strategic expansion in the digital asset sector.
- Financing Support: The transaction included a $9.6 million PIPE financing, providing essential growth capital to support the acquisition of next-generation mining equipment and the expansion of energy-efficient infrastructure, thereby enhancing mining operations.
- Technological Edge: Newly deployed ElphaPex mining rigs are expected to be operational within 60 days, delivering up to 43,200 GH/s of hash rate, further solidifying United Dogecoin's position in a competitive market.
- Strategic Integration: E.F. Hutton played a crucial role in transaction structuring, stakeholder alignment, and capital raising, ensuring the smooth execution of the deal and laying the groundwork for future growth strategies.
See More

Exclusive M&A Advisory: Hutton & Co. has completed a merger involving a pharmaceutical company, focusing on the creation of a significant public entity in the cryptocurrency sector.
Largest Dogecoin Miner: The merger aims to establish the largest public Dogecoin mining operation, enhancing the company's position in the cryptocurrency market.
See More
- Merger Agreement Signed: Shuttle Pharma has signed a definitive merger agreement with United Dogecoin, expected to transform Shuttle Pharma into the world's largest public Dogecoin miner, issuing 8,000 shares of Series B-1 convertible preferred stock convertible into approximately 32.3 million common shares at $1.24 each, representing a 20% upside from Thursday's closing price.
- Private Investment Support: The transaction will also be bolstered by an $11 million private investment, enhancing the merged company's capital base and positioning it favorably in the competitive cryptocurrency market, particularly in Dogecoin mining.
- Mining Rig Deployment Plan: United Dogecoin plans to deploy up to 3,000 next-generation ElphaPex mining rigs within 60 days post-closing, projected to contribute about 1.5% of the global Dogecoin network capacity, thereby increasing the merged company's market competitiveness.
- Retail Investor Sentiment Shift: Retail sentiment for SHPH on Stocktwits shifted from 'bullish' to 'extremely bullish', with message volumes surging 7,000% in 24 hours, reflecting strong investor confidence in the merger's prospects, despite the stock's nearly 45% decline this year.
See More
- Enhanced Platform Capabilities: Shuttle Pharma's molecule.ai platform significantly improves the evaluation and prioritization of therapeutic candidates through new models, thereby accelerating drug development processes and enhancing decision-making confidence and efficiency.
- Multi-Step Reasoning System: The newly unveiled autonomous AI agent system enables multi-step reasoning and multi-agent orchestration, dramatically reducing manual effort and increasing throughput for research teams, thus advancing automation in scientific workflows.
- Cost and Time Optimization: By integrating reasoning, prediction, and automation, molecule.ai has the potential to materially reduce timelines and costs while increasing success rates, further solidifying the company's leadership in AI-driven biopharma innovation.
- Long-Term Value Creation: Shuttle Pharma remains focused on expanding molecule.ai's capabilities to unlock new therapeutic opportunities, improve development efficiency, and create long-term value for shareholders, showcasing its competitive advantage in the future market.
See More









